Cutler Group LP Catalent, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Catalent, Inc. stock. As of the latest transaction made, Cutler Group LP holds 600 shares of CTLT stock, worth $38,088. This represents 0.01% of its overall portfolio holdings.

Number of Shares

600

Previous 2,197 72.69%

Holding current value

$38,088

Previous $98,000 66.33%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$42.56 - $59.82 $67,968 - $95,532	-1,597 Reduced 72.69%	600 $33,000
Q4 2023 Jan 18, 2024	SELL	$32.18 - $46.57 $34,303 - $49,643	-1,066 Reduced 32.67%	2,197 $98,000
Q3 2023 Nov 07, 2023	SELL	$44.2 - $50.2 $70,145 - $79,667	-1,587 Reduced 32.72%	3,263 $148,000
Q2 2023 Jul 18, 2023	BUY	$31.86 - $67.26 $140,343 - $296,280	4,405 Added 989.89%	4,850 $210,000
Q1 2023 May 01, 2023	BUY	$45.44 - $74.26 $20,220 - $33,045	445 New	445 $29,000
Q2 2022 Aug 04, 2022	SELL	$87.2 - $114.05 $122,080 - $159,670	-1,400 Closed	0 $0
Q1 2022 Apr 14, 2022	BUY	$94.19 - $124.49 $23,547 - $31,122	250 Added 21.74%	1,400 $155,000
Q4 2021 Jan 18, 2022	BUY	$119.57 - $139.07 $58,589 - $68,144	490 Added 74.24%	1,150 $147,000
Q3 2021 Oct 26, 2021	BUY	$109.17 - $142.35 $72,052 - $93,951	660 New	660 $87,000
Q1 2021 Apr 26, 2021	SELL	$101.51 - $125.27 $1,015 - $1,252	-10 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$85.88 - $105.36 $858 - $1,053	10 New	10 $1,000
Q1 2018 May 11, 2018	SELL	$39.4 - $47.39 $3,940 - $4,739	-100 Closed	0 $0
Q4 2017 Jan 17, 2018	BUY	$37.27 - $43.02 $3,727 - $4,302	100	100 $4,000

Others Institutions Holding CTLT

# of Institutions

514

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account